Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma

Modern Pathology

Volumn 24, Issue 5, 2011, Pages 739-749

  Chen, Jey Hsin ^a,b   Faquin, William C ^c   Lloyd, Ricardo V ^d,e   Nosé, Vnia ^a,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MAYO CLINIC ROCHESTER   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

columnar cell variant; cyclin D1; papillary thyroid carcinoma; catenin

Indexed keywords

B RAF KINASE; BETA CATENIN; CYCLIN D1; DOXORUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; COLUMNAR CELL VARIANT; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGIONAL METASTASIS; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME;

EID: 79955619784     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.2     Document Type: Article

References (81)

1. Akslen LA, Varhaug JE. Thyroid carcinoma with mixed tall-cell and columnar-cell features. Am J Clin Pathol 1990;94:442-445. (Pubitemid 20316572)
2. Evans HL. Columnar-cell carcinoma of the thyroid. a report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol 1986;85:77-80. (Pubitemid 16166045)
3. Berends D, Mouthaan PJ. Columnar-cell carcinoma of the thyroid. Histopathology 1992;20:360-362.
4. Gaertner EM, Davidson M, Wenig BM. The columnar cell variant of thyroid papillary carcinoma. case report and discussion of an unusually aggressive thyroid papillary carcinoma. Am J Surg Pathol 1995;19: 940-947.
5. Mizukami Y, Nonomura A, Michigishi T, et al. Columnar cell carcinoma of the thyroid gland: a case report and review of the literature. Hum Pathol 1994;25:1098-1101. (Pubitemid 24313656)
6. Sobrinho-Simoes M, Nesland JM, Johannessen JV. Columnar-cell carcinoma. another variant of poorly differentiated carcinoma of the thyroid. Am J Clin Pathol 1988;89:264-267. (Pubitemid 18057184)
7. Evans HL. Encapsulated columnar-cell neoplasms of the thyroid. a report of four cases suggesting a favorable prognosis. Am J Surg Pathol 1996;20:1205-1211. (Pubitemid 26336844)
8. Ferreiro JA, Hay ID, Lloyd RV. Columnar cell carcinoma of the thyroid: report of three additional cases. Hum Pathol 1996;27:1156-1160. (Pubitemid 26374934)
9. Wenig BM, Thompson LD, Adair CF, et al. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. Cancer 1998;82:740-753. (Pubitemid 28090287)
10. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
11. Delellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol 2006;94:662-669.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the braf gene in human cancer. Nature 2002;417:949-954. (Pubitemid 34716871)
13. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of braf mutations in thyroid cancer: genetic evidence for constitutive activation of the Ret/Ptc-Ras-Braf signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457. (Pubitemid 36373628)
14. Xing M. Braf mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-762. (Pubitemid 350294294)
15. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the Raf-Erk signaling pathway by onco-genic mutations of B-Raf. Cell 2004;116:855-867. (Pubitemid 38410730)
16. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot braf mutation, V599e, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-4397. (Pubitemid 37153748)
17. Sedliarou I, Saenko V, Lantsov D, et al. The Braf T1796a transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 2004;25: 1729-1735.
18. Nikiforova MN, Kimura ET, Gandhi M, et al. Braf mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-5404. (Pubitemid 37452745)
19. Schmidt J, Derr V, Heinrich MC, et al. Braf in papillary thyroid carcinoma of ovary (Struma Ovarii). Am J Surg Pathol 2007;31:1337-1343. (Pubitemid 47329669)
20. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of Braf V600e mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110: 38-46.
21. Xing M, Westra WH, Tufano RP, et al. Braf mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90: 6373-6379. (Pubitemid 41759286)
22. Xu X, Quiros RM, Gattuso P, et al. High prevalence of Braf gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63: 4561-4567. (Pubitemid 36951030)
23. Delellis RA, Lloyd RV, Heitz PU, et al. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press: Lyon, 2004.
24. Jin L, Sebo TJ, Nakamura N, et al. Braf mutation analysis in fine needle aspiration (Fna) cytology of the thyroid. Diagn Mol Pathol 2006;15:136-143. (Pubitemid 44325474)
25. Nakamura N, Carney JA, Jin L, et al. Rassf1a and Nore1a methylation and Brafv600e mutations in thyroid tumors. Lab Invest 2005;85:1065-1075. (Pubitemid 43073981)
26. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th edn. Springer: New York, London, 2009.
27. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006;13:119-128.
28. Garcia-Rostan G, Camp RL, Herrero A, et al. Beta-Catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, And Ctnnb1 Exon 3 Mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001;158:987-996. (Pubitemid 32221790)
29. Garcia-Rostan G, Tallini G, Herrero A, et al. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999;59: 1811-1815. (Pubitemid 29186147)
30. Lazzereschi D, Sambuco L, Carnovale Scalzo C, et al. Cyclin D1 and Cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer 1998;76:806-811. (Pubitemid 28262097)
31. Tallini G, Garcia-Rostan G, Herrero A, et al. Down-regulation of P27kip1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol 1999;23:678-685. (Pubitemid 29262831)
32. Wang S, Lloyd RV, Hutzler MJ, et al. The role of cell cycle regulatory protein, Cyclin D1, in the progression of thyroid cancer. Mod Pathol 2000;13:882-887. (Pubitemid 30643836)
33. Hui PK, Chan JK, Cheung PS, et al. Columnar cell carcinoma of the thyroid. fine needle aspiration findings in a case. Acta Cytol 1990;34:355-358. (Pubitemid 20182057)
34. Fukunaga M, Shinozaki S, Miyazawa Y, et al. Columnar cell carcinoma of the thyroid. Pathol Int 1997;47: 489-492. (Pubitemid 27280173)
35. Genton CY, Dutoit M, Portmann L, et al. Pathologic fracture of the femur neck as first manifestation of a minute columnar cell carcinoma of the thyroid gland. Pathol Res Pract 1998;194:861-863. (Pubitemid 29012249)
36. Hirokawa M, Shimizu M, Fukuya T, et al. Columnar cell carcinoma of the thyroid: Mib-1 immunoreactivity as a prognostic factor. Endocr Pathol 1998;9:31-34. (Pubitemid 28304403)
37. Jayaram G. Cytology of columnar-cell variant of papillary thyroid carcinoma. Diagn Cytopathol 2000;22:227-229. (Pubitemid 30185817)
38. Barton CP III, Brennan JA, Lowry TR, et al. Columnar cell variant of papillary thyroid carcinoma. Ear Nose Throat J 2006;85:640, 643.
39. Kini H, Pai RR, Kalpana S. Solitary parotid metastasis from columnar cell carcinoma of the thyroid: a diagnostic dilemma. Diagn Cytopathol 2003;28:72-75. (Pubitemid 36159594)
40. Huang WT, Yang SF, Wang SL, et al. Encapsulated columnar-cell carcinoma of the thyroid: a case report. Kaohsiung J Med Sci 2005;21:241-244.
41. Watanabe K, Tsubota H, Himi T, et al. Columnar-cell carcinoma of the thyroid. Auris Nasus Larynx 2001;28:269-273. (Pubitemid 32727402)
42. Shimizu M, Hirokawa M, Manabe T. Tall cell variant of papillary thyroid carcinoma with foci of columnar cell component. Virchows Arch 1999;434:173-175. (Pubitemid 29184996)
43. Smith AE, Couch M, Argani P. Pathologic quiz case 1. papillary thyroid carcinoma (Ptc), combined tall cell and columnar variants. Arch Otolaryngol Head Neck Surg 1998;124:11702.
44. Ylagan LR, Dehner LP, Huettner PC, et al. Columnar cell variant of papillary thyroid carcinoma. report of a case with cytologic findings. Acta Cytol 2004;48:73-77. (Pubitemid 38166515)
45. Zagar I, Vidergar-Kralj B, Schwarzbartl-Pevec AA, et al. Columnar cell thyroid carcinoma-diagnostic dilemmas and pitfalls. Nucl Med Rev Cent East Eur 2003;6: 155-158. (Pubitemid 38181480)
46. Yunta PJ, Ponce JL, Prieto M, et al. The importance of a tumor capsule in columnar cell thyroid carcinoma: a report of two cases and review of the literature. Thyroid 1999;9:815-819. (Pubitemid 29409666)
47. Perez F, Llobet M, Garijo G, et al. Fine-needle aspiration cytology of columnar-cell carcinoma of the thyroid: report of two cases with cytohistologic correlation. Diagn Cytopathol 1998;18:352-356. (Pubitemid 28199069)
48. Putti TC, Bhuiya TA. Mixed columnar cell and tall cell variant of papillary carcinoma of thyroid: a case report and review of the literature. Pathology 2000;32:286-289.
49. Ciampi R, Nikiforov YE. Alterations of the braf gene in thyroid tumors. Endocr Pathol 2005;16:163-172. (Pubitemid 41687187)
50. Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-Rafv600e mutation and clinicopathologic parameters in papillary thyroid carcinoma: data from a multicentric italian study and review of the literature. Endocr Relat Cancer 2006;13:455-464. (Pubitemid 43886668)
51. Cohen Y, Xing M, Mambo E, et al. Braf mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-627. (Pubitemid 36553510)
52. Begum S, Rosenbaum E, Henrique R, et al. Braf mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 2004;17:1359-1363. (Pubitemid 39472990)
53. Carr NJ, Mahajan H, Tan KL, et al. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of braf mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol 2009;62:516-518.
54. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumor-igenesis: Raf/Ras oncogenes and mismatch-repair status. Nature 2002;418:934. (Pubitemid 34976022)
55. Pollock PM, Harper UL, Hansen KS, et al. High frequency of braf mutations in nevi. Nat Genet 2003;33:19-20. (Pubitemid 36068675)
56. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with Braf and Kras mutations in colorectal neoplasia. Cancer Res 2002;62:6451-6455. (Pubitemid 35364105)
57. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108. (Pubitemid 26099813)
58. Hunter T, Pines J. Cyclins and cancer. II: cyclin D and cdk inhibitors come of age. Cell 1994;79:573-582. (Pubitemid 24363801)
59. Katoh R, Bray CE, Suzuki K, et al. Growth Activity In Hyperplastic And Neoplastic Human Thyroid Determined By An Immunohistochemical Staining Procedure Using Monoclonal Antibody Mib-1. Hum Pathol 1995;26:139-146.
60. Khoo ML, Ezzat S, Freeman JL, et al. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 2002;87: 1810-1813. (Pubitemid 34615273)
61. Letsas KP, Frangou-Lazaridis M, Skyrlas A, et al. Transcription factor-mediated proliferation and apop-tosis in benign and malignant thyroid lesions. Pathol Int 2005;55:694-702. (Pubitemid 41726935)
62. Muro-Cacho CA, Holt T, Klotch D, et al. Cyclin D1 expression as a prognostic parameter in papillary carcinoma of the thyroid. Otolaryngol Head Neck Surg 1999;120:200-207. (Pubitemid 29077532)
63. Saltman B, Singh B, Hedvat CV, et al. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 2006;140:899-905.
64. Wang S, Wuu J, Savas L, et al. The role of cell cycle regulatory proteins, Cyclin D1, Cyclin E, and P27 in thyroid carcinogenesis. Hum Pathol 1998;29:1304-1309. (Pubitemid 28525534)
65. Tetsu O, Mccormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426. (Pubitemid 29180374)
66. Lantsov D, Meirmanov S, Nakashima M, et al. Cyclin D1 overexpression in thyroid papillary microcarcino-ma: its association with tumour size and aberrant beta-catenin expression. Histopathology 2005;47: 248-256. (Pubitemid 41243262)
67. Ishigaki K, Namba H, Nakashima M, et al. Aberrant localization of beta-catenin correlates with overexpres-sion of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 2002;87:3433-3440. (Pubitemid 34816401)
68. Siironen P, Nordling S, Louhimo J, et al. Immunohis-tochemical expression of Bcl-2, Ki-67, and P21 in patients with papillary thyroid cancer. Tumour Biol 2005;26:50-56. (Pubitemid 40529298)
69. Coqueret O. Linking cyclins to transcriptional control. Gene 2002;299:35-55. (Pubitemid 35379826)
70. Donghi R, Longoni A, Pilotti S, et al. Gene P53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:1753-1760. (Pubitemid 23127381)
71. Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the P53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179-184. (Pubitemid 23037270)
72. Ito T, Seyama T, Mizuno T, et al. Unique association of P53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369-1371.
73. Ito T, Seyama T, Mizuno T, et al. Genetic alterations in thyroid tumor progression: association with P53 gene mutations. Jpn J Cancer Res 1993;84:526-531. (Pubitemid 23193811)
74. Moore D, Ohene-Fianko D, Garcia B, et al. Apoptosis in thyroid neoplasms: relationship with P53 and Bcl-2 expression. Histopathology 1998;32:35-42.
75. Nakamura T, Yana I, Kobayashi T, et al. P53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 1992;83:1293-1298. (Pubitemid 23029837)
76. Ron E, Kleinerman RA, Boice JD Jr, et al. A population-based case-control study of thyroid cancer. J Natl Cancer Inst 1987;79:1-12. (Pubitemid 17102544)
77. Mctiernan AM, Weiss NS, Daling JR. Incidence of thyroid cancer in women in relation to reproductive and hormonal factors. Am J Epidemiol 1984;120:423-435. (Pubitemid 14032090)
78. Hiasa Y, Nishioka H, Kitahori Y, et al. Immunohisto-chemical analysis of estrogen receptors in 313 paraffin section cases of human thyroid tissue. Oncology 1993;50:132-136. (Pubitemid 23098733)
79. Chaudhuri PK, Prinz R. Estrogen receptor in normal and neoplastic human thyroid tissue. Am J Otolaryngol 1989;10:322-326. (Pubitemid 19261458)
80. Diaz NM, Mazoujian G, Wick MR. Estrogen-receptor protein in thyroid neoplasms. an immunohistochem-ical analysis of papillary carcinoma, follicular carcinoma, and follicular adenoma. Arch Pathol Lab Med 1991;115:1203-1207.
81. Tavangar SM, Monajemzadeh M, Larijani B, et al. Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. Singapore Med J 2007;48:744-747. (Pubitemid 351235329)